Abstract: The present invention provides the use of ATP for the manufacture of a medicine comprising ATP as an active ingredient for exerting a preventive or therapeutic pharmacological effect when administered to a mammal, preferably a human, selected from the group consisting of: a. modulating oxidative stress and the effects thereof by favourably affecting the formation or scavenging of aggressive hydroxyl radicals; b. modulating the inflammatory response to a strong external insult such as endotoxin (LPS) and/or phytohaemagglutinin, even under conditions of severe oxidative stress; c. inhibiting the inflammatory response to a strong external insult such as endotoxin (LPS) and/or phytohaemagglutinin under conditions of severe oxidative stress; d. exerting a local protective effect against oxidative stress in the intestine, thus preventing intestinal damage induced by several types of medication such as non steroid anti-inflammatory drugs (NSAIDs); e.

Abstract: The present invention relates to methods for the identification of compounds that increase or decrease the inhibitory effect of TFPI on tissue factor activity and/or Factor Xa activity and/or thrombin formation. The invention also relates to methods for the identification of compounds that increase or decrease the co-factor activity of Protein S in TFPI-mediated inhibition of tissue factor and/or Factor Xa activity. This invention also relates to a pharmaceutical composition comprising the compounds identifiable by such methods. The invention also relates to methods for the regulation of tissue factor activity by influencing the interaction between Protein S and Tissue Factor Pathway Inhibitor.

Abstract: A food supplement of therapeutic composition is provided suitable for the treatment or prophylaxis of COPD and other acute or chronic diseases in a mammal, especially a human being, comprising at least one of glutamate, other than mono sodium glutamate, and a precursor of glutamate selected from the group consisting of leucine, valine, isoleucine, and a keto acid thereof, in a daily dose for said mammal of at least 6 grams, preferably between 9 and 20 grams, of the total of said glutamate and precursor forms thereof.

Abstract: The present invention provides the use of ATP for the manufacture of a medicine for exerting a pharmacological effect when administered to a mammal, preferably a human, selected from the group consisting of: 1°. modulating inflammation by inhibiting the inflammatory response to a strong external insult such as endotoxin (LPS) and/or phytohaemagglutinin; 2°. exerting said inhibitory effect on inflammatory response to an external stimulus even under conditions of oxidative stress, 3°. exerting a local immuno-modulating and anti-inflammatory effect in the intestine, thus preventing intestinal damage induced by a non-steroid anti-inflammatory drug (NSAIDs), 4°. exerting an immuno-modulating and anti-inflammatory effect in human intestinal cells in vitro, 5°. alleviating pulmonary symptoms, such as shortness of breath and dyspnoea, in patients suffering from an obstructive pulmonary disease, and 6°.